19288-90-5

Usage

Type of compound

Dichloride derivative of malonyl hydrazide

State at room temperature

Solid

Use in organic synthesis

Versatile building block for the preparation of various organic compounds

Reactivity

Can form hydrazones, valuable in the development of new organic molecules

Applications

Pharmaceuticals, agrochemicals, and materials science

Potential properties

Antiviral and antimicrobial, of interest for medicinal chemistry research.

Upstream product

• 40885-82-3 2-(phenylhydrazono)malonic acid 
• 10026-13-8 phosphorus pentachloride 
• 100-63-0 phenylhydrazine 
• 6134-59-4 diethyl 2-(phenylhydrazono)malonate 
• 142-04-1 aniline hydrochloride 

Downstream Products

• 18514-85-7 4-oxo-1,4-dihydrocinnoline-3-carboxylic acid 
• 161455-86-3 1-(4-Methoxy-benzyl)-5-phenyl-3-(phenyl-hydrazono)-1,5-dihydro-benzo[b][1,4]diazepine-2,4-dione 
• 161455-91-0 2-[2,4-Dioxo-5-phenyl-3-(phenyl-hydrazono)-2,3,4,5-tetrahydro-benzo[b][1,4]diazepin-1-yl]-N-isopropyl-N-phenyl-acetamide 
• 187148-55-6 1,5-Bis-(3-methyl-butyl)-3-(phenyl-hydrazono)-1,5-dihydro-benzo[b][1,4]diazepine-2,4-dione 
• 187148-54-5 1-Benzyl-5-(3-methyl-butyl)-3-(phenyl-hydrazono)-1,5-dihydro-benzo[b][1,4]diazepine-2,4-dione 
• 160917-87-3 1-Adamantan-1-ylmethyl-5-(3-methyl-butyl)-3-(phenyl-hydrazono)-1,5-dihydro-benzo[b][1,4]diazepine-2,4-dione 
• 187148-57-8 1,5-Bis-(2-cyclopentyl-1-methyl-ethyl)-3-(phenyl-hydrazono)-1,5-dihydro-benzo[b][1,4]diazepine-2,4-dione 
• 160917-90-8 1-Adamantan-1-ylmethyl-5-cyclohexyl-3-(phenyl-hydrazono)-1,5-dihydro-benzo[b][1,4]diazepine-2,4-dione 
• 151385-79-4 1-(3-Methyl-butyl)-5-phenyl-3-(phenyl-hydrazono)-1,5-dihydro-benzo[b][1,4]diazepine-2,4-dione 
• 151385-90-9 7-Fluoro-5-(3-methyl-butyl)-1-phenyl-3-(phenyl-hydrazono)-1,5-dihydro-benzo[b][1,4]diazepine-2,4-dione 
• 151385-65-8 2,4-dioxo-5-N-(2-fluorophenyl)-1-N-(3-methylbut-1-yl)-3-phenylhydrazono-2,3,4,5-tetrahydro-1H-1,5-benzodiazepine 
• 206360-68-1 (R)-4-[5-Adamantan-1-ylmethyl-2,4-dioxo-3-(phenyl-hydrazono)-2,3,4,5-tetrahydro-benzo[b][1,4]diazepin-1-ylmethyl]-2,2-dimethyl-oxazolidine-3-carboxylic acid tert-butyl ester 
• 307966-78-5 1-N-(1,3-dimethylbut-1-yl)-2,4-dioxo-5-N-phenyl-3-phenylhydrazono-2,3,4,5-tetrahydro-1H-1,5-benzodiazepine 
• 151385-68-1 1-N-(3,3-dimethylbut-1-yl)-2,4-dioxo-5-N-(2-fluorophenyl)-3-phenylhydrazono-2,3,4,5-tetrahydro-1H-1,5-benzodiazepine 

Relevant academic research and scientific papers

Synthesis and Structure-Affinity Relationship of Small Molecules for Imaging Human CD80 by Positron Emission Tomography

The costimulatory molecule CD80 is an early marker for immune activation. It is upregulated on activated antigen-presenting cells. We aimed at developing a tracer for imaging CD80 by positron emission tomography (PET). Novel CD80 ligands were synthesized

Distinct CCK-2 receptor conformations associated with β-arrestin-2 recruitment or phospholipase-C activation revealed by a biased antagonist

Seven-transmembrane receptors (7TMRs), also termed G protein-coupled receptors (GPCRs), form the largest class of cell surface membrane receptors, involving several hundred members in the human genome. Nearly 30% of marketed pharmacological agents target

Novel benzodiazepine photoaffinity probe stereoselectively labels a site deep within the membrane-spanning domain of the cholecystokinin receptor

An understanding of the molecular basis of drug action provides opportunities for refinement of drug properties and for development of more potent and selective molecules that act at the same biological target. In this work, we have identified the active

Solid phase synthesis of 6-acylamino-1-alkyl/aryl-4-oxo-1,4- dihydrocinnoline-3-carboxamides

6-Acylmino-1-alkyl/aryl-4-oxo-1,4-dihydrocinnoline-3-carboxamides were synthesized in parallel from 6-nitro-4-oxo-1,4-dihydrocinnoline-3-carboxylic acid. The latter formed amides with amines bound to polystyrene-based resins via acid-labile linkers. N1 an

IMMUNOMODULATING HETEROCYCLIC COMPOUNDS

Compounds of formula (I) are inhibitors of CD80 and useful in immunomodulation therapy: wherein R1 and R3 independently represent H; F; CI; Br; -NO2; -CN; C1-C6 alkyl optionally substituted by F or Cl; or C1-C6 alkoxy optionally substituted by F; R4 represents a carboxylic acid group (-COOH) or an ester thereof, or -C(=O)NR6R7, -NR7C(=O)R6, -NR7C(=O)OR6, -NHC(=O)NR7R6 or -NHC(=S)NR7R6 wherein R6 represents H, or a radical of formula - (Alk)m-Q wherein m is 0 or 1, Alk is an optionally substituted divalent straight or branched C1-C12 alkylene, or C2-C12 alkenylene, or C2-C12 alkynylene radical or a divalent C3-C12 carbocyclic radical, any of which radicals may contain one or more -O-, -S- or -N(R8)- links wherein R8 represents H or C1-C4 alkyl, C3--C4 alkenyl, C3-C4 alkynyl, or C3-C6 cycloalkyl, and Q represents H; -NR9R10 wherein R9 and R10 independently represents H; C1-C4 alkyl; C3-C4 alkenyl; C3-C4 alkynyl; C3-C6 cycloalkyl; an ester group; an optionally substituted carbocyclic or heterocyclic group; or R9 and R10 form a ring when taken together with the nitrogen to which they are attached, which ring is optionally substituted; and R7 represents H or C1-C6 alkyl; or when taken together with the atom or atoms to which they are attached R6 and R7 form an optionally substituted monocyclic heterocyclic ring having 5, 6 or 7 ring atoms; and X represents a bond or a divalent radical of formula - (Z)n-(Alk)- or - (Alk)-(Z)n- -wherein Z represents -O-, -S- or -NH-, Alk is as defined in relation to R6 and n is 0 or 1.

Use of 1,5-benzo?b!1,4-diazepines to control gastric emptying

A method of controlling gastric emptying in patients having an early non-insulin-dependent diabetic condition and exhibiting rapid gastric emptying comprising the administration of an effective gastric emptying controlling amount of a compound of Formula

CCK OR GASTRIN MODULATING 5-HETEROCYCLIC-1, 5 BENZODIAZEPINES

Compounds of general formula (I) and physiologically salts thereof, processes for their preparation and their use as modulators of the effects of gastrin and CCK.

Novel 1,5-benzodiazepindione gastrin/CCK(B) antagonists

The development of a potent, selective and orally bioavailable 1,5-benzodiazepindione gastrin/CCK(B) receptor antagonist (compound 7, GR199114X) is described.

Discovery of 1,5-benzodiazepines with peripheral cholecystokinin (CCK-A) receptor agonist activity. 1. Optimization of the agonist "trigger"

Directed screening of compounds selected from the Glaxo registry file for contractile activity on the isolated guinea pig gallbladder (GPGB) identified a series of 1,5-benzodiazepines with peripheral cholecystokinin (CCK) receptor agonist activity. Agonis